CoreValve Evolut Pro Prospective Registry

NCT03423459 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-05-26

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the real-world performance of the CoreValve Evolut PRO transcatheter aortic valve, including leaflet function, in a prospective observational registry.

Conditions

  • Aortic Stenosis

Interventions

DEVICE

TAVR

Transcatheter Aortic Valve Replacement

Sponsors & Collaborators

  • Medtronic Cardiovascular

    collaborator INDUSTRY
  • Medstar Health Research Institute

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-18
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03423459 on ClinicalTrials.gov